These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1167 related articles for article (PubMed ID: 9607572)

  • 1. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
    Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
    J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
    Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
    Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
    Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
    Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
    Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
    Gerrits CJ; Burris H; Schellens JH; Planting AS; van den Burg ME; Rodriguez GI; van Beurden V; Loos WJ; Hudson I; Fields S; Verweij J; von Hoff DD
    Eur J Cancer; 1998 Jun; 34(7):1030-5. PubMed ID: 9849451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
    Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
    Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
    Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
    J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.